Innovation Pharmaceuticals Inc (IPIX)

[PJ007]

Brilacidin mentioned in another paper:

https://www.sciencedirect.com/science/article/pii/S0045206823002614


4.2. Antibacterial drugs
The guanidine-derivatives currently being evaluated as potential antibacterial drugs for different types of bacterial infections are presented in Table 9. These compounds are under clinical development at phase 1/phase 2 for the treatment of acute bacterial infections, MRSA, and fungal infections. In detail, Brilacidin is a non-peptide defensin-mimetic small molecule being evaluated for the treatment of acute bacterial skin and skin structure infections [163], [164]. LTX-109 is a broad-spectrum, fast-acting bactericidal antimicrobial drug candidate for the treatment of bacterial skin infections, fungal infections, and nasal decolonization of MRSA and acts by disruption of the membrane and cell lysis [165], [166].